As It Happens: Drug buy-busts and operations philstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philstar.com Daily Mail and Mail on Sunday newspapers.
About OneNews
OneNews.PH is the online presence of OneNews, the all-news channel of Cignal TV and the synergy of the journalistic strengths of The Philippine STAR, philstar.com, TV5 Network Inc. and BusinessWorld under Mediaquest Holdings Inc.
About Leronlimab (PRO 140)
Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9
CytoDyn Inc.May 7, 2021 GMT
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9
VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its drug candidate, leronlimab, will be featured in a one-hour news segment on Sunday, May 9, at 5:00 pm PT / 8:00 pm ET on OneNews in the Philippines. CytoDyn has been supplying leronlimab to the Philippines as a therapeutic treatment for critically ill COVID-19 patients under Compassionate Special Permits (CSPs) authorized by the Philippine FDA.
NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the company s acquisition of Low Energy Cartridge (LEC) systems and the go-to-market strategy for the LEC, the world s first cartridge based non-lethal weapon system. Interested parties can email questions to investors@kwesst.com prior to or during the meeting. To dial in, call 647-374-4685 in Canada or 929-205-6099 in the US. One priority for KWESST is to begin the commercialization of the LEC system with an accelerated plan in response to market interest and high growth across all segments of the non-lethal market. In this market
NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the company s acquisition of Low Energy Cartridge (LEC) systems and the go-to-market strategy for the LEC, the world s first cartridge based non-lethal weapon system. Interested parties can email questions to investors@KWESST.com prior to or during the meeting. To dial in, call 647-374-4685 in Canada or 929-205-6099 in the US. One priority for KWESST is to begin the commercialization of the LEC system with an accelerated plan in response to market interest and high growth across all segments of the non-lethal market. In this market